The aim of this phase II study was to evaluate the efficacy and safety of two doses (10 and 5Â mg) of olanzapine in combination with standard antiemetic treatment (aprepitant, palonosetron, and dexamethasone) for patients receiving highly emetogenic chemotherapy (HEC).